Is grief a treatable condition?

Normal grief is not a disorder and does not need a clinical fix. Prolonged grief disorder, which the DSM-5-TR defines as severe yearning, preoccupation, and identity disruption that persists at least 12 months after a loss, is a diagnosable condition with structured treatments. The strongest evidence supports a grief-specific psychotherapy called Complicated Grief Treatment, not medication.

Will ketamine make me forget my person?

No. Ketamine does not erase memories or attachments, and we would not want it to. The integration model in any ketamine work is about learning to carry a loss alongside the rest of your life, not removing the love that produced the grief in the first place. Healthy grieving keeps the relationship intact in a new form.

Should I see a therapist before considering ketamine?

For most grieving people, yes, and we will say so directly. A grief-trained therapist using a structured approach such as Complicated Grief Treatment has the strongest evidence base. Ketamine is not a replacement for the relational and meaning-making work of grief, and we are comfortable telling people the right next step is a therapist, not us.

What if my grief has turned into depression?

That happens, and it is a different conversation. If a clinician determines you meet criteria for a major depressive episode, the existing ketamine evidence for treatment-resistant depression applies. We screen carefully during consultation, ask about prior diagnoses, and coordinate with your prescribing provider before treatment. Talk to your clinician about whether what you are experiencing is bereavement, depression, or both.

Is there a right time after a loss to consider ketamine?

There is no fixed answer, and we do not recommend ketamine in the acute weeks after a loss. Acute grief is painful but expected. When grief stays stuck in the same severe pattern many months out, when it is destroying functioning, or when it has crossed into a diagnosable depression, it is reasonable to talk with a clinician about all options. Anesthesia-level monitoring is part of every session if treatment proceeds.

Ketamine for Grief: A Careful Look at What's Possible

Grief is not depression — the DSM-5-TR's bright line

Grief is the price of love. It is not a malfunction. For most people who have lost someone they love, the waves of yearning, the hollow days, the disbelief that the world keeps moving — these are not symptoms of an illness. They are evidence that someone mattered. Pathologizing normal mourning by calling it depression and reaching for a prescription is one of the more harmful things a clinic can do.

That is the starting line for any honest conversation about ketamine and grief. We are not interested in selling treatment to a grieving person whose pain, however severe, is following the difficult-but-expected arc of bereavement. We are interested in being useful to the much smaller subset of people whose grief has stopped moving — people for whom something has gone wrong in the integration process, or whose grief has crossed into a different diagnosable condition entirely.

The American Psychiatric Association, in the 2022 release of the DSM-5-TR, formally recognized this distinction by adding prolonged grief disorder (PGD) as a stand-alone diagnosis. That decision followed roughly two decades of research showing that a meaningful minority of bereaved adults — estimates cluster around 7 to 10 percent — develop a persistent, severe pattern of grief that is functionally and biologically distinguishable from both major depression and PTSD.

What prolonged grief disorder actually requires

The DSM-5-TR criteria for prolonged grief disorder are strict on purpose. The diagnosis requires that, at least 12 months after the death of someone close (six months in children and adolescents), the bereaved person experiences persistent and pervasive grief characterized by intense yearning or longing for the deceased, preoccupation with thoughts or memories of the deceased, and at least three of the following on most days: identity disruption, marked sense of disbelief about the death, avoidance of reminders, intense emotional pain, difficulty reintegrating into relationships and activities, emotional numbness, a sense that life is meaningless, or intense loneliness.

The criteria also require that the disturbance causes clinically significant distress or impairment, exceeds expected social and cultural norms for grief, and is not better explained by another mental disorder. That last clause matters. If a person meets criteria for major depressive disorder, you treat the depression. If they meet criteria for PTSD because the death was traumatic, you treat the PTSD. The PGD label is reserved for the cases where the grief itself, not a co-occurring condition, is the primary problem.

A 2017 paper by Boelen and Smid in BMJ made the case clearly: prolonged grief disorder is distinct from both major depression and PTSD, and patients require grief-specific treatment frameworks rather than generic antidepressant or trauma protocols. The neurobiology, the clinical features, and the treatment response are all different enough to merit a different category.

Why we will not medicalize normal mourning

If you came here hoping for an article that describes a stuck, crushing grief and immediately points toward an infusion, this is not that article. Normal grief — even severe normal grief — does not need ketamine. It needs people, time, ritual, sleep, and, often, a good therapist. Most of what makes grief survivable is relational and meaning-based, not pharmacological.

The strongest treatment evidence in the bereavement literature is for a structured psychotherapy. A 2016 randomized trial by Shear and colleagues in JAMA Psychiatry compared Complicated Grief Treatment (CGT), a 16-session protocol focused on accepting the reality of the loss and restoring a sense of meaning, against standard interpersonal psychotherapy. CGT outperformed the comparator for prolonged and complicated grief, with response rates that have held up across multiple Shear-group trials over the last decade. That kind of effect size, in this population, is the bar that any other intervention has to clear.

Ketamine has not cleared that bar. There is no published randomized controlled trial of ketamine specifically for prolonged grief disorder as of this writing. We are not aware of one. And in the absence of grief-specific trial data, the responsible move is to defer to what does work — structured grief therapy with a trained clinician — rather than to import evidence from adjacent conditions and pretend it travels.

Where the depression evidence does apply

Grief and depression overlap, but they are not the same. Some bereaved people develop a major depressive episode in the months and years after a loss. When that happens, the clinical picture changes, and so do the treatment options. A person who meets criteria for treatment-resistant depression — failure to respond to two or more adequate trials of antidepressants — has a body of ketamine research behind them.

The most-cited example is the Murrough et al. randomized controlled trial, published in The American Journal of Psychiatry in 2013, which compared a single IV ketamine infusion to midazolam in patients with treatment-resistant depression. At 24 hours, 64 percent of the ketamine group met response criteria, compared with 28 percent of the midazolam group. That pattern — rapid antidepressant response in patients who had failed conventional medications — has since been replicated in dozens of trials and is the basis for the broader off-label use of racemic ketamine in mood disorders, as well as the FDA approval of esketamine (Spravato) for treatment-resistant depression and for major depressive disorder with acute suicidal ideation.

None of that data was collected in grieving populations specifically. Bereavement is typically an exclusion criterion in depression trials. So when we say the evidence applies, what we mean is narrower: if a clinician determines that a bereaved person meets criteria for an active, treatment-resistant major depressive episode, the standard depression evidence is the relevant evidence — not because depression and grief are the same, but because the diagnosis has crossed a line.

Ketamine is FDA-approved as an anesthetic; its use for depression and any psychiatric condition outside esketamine's specific indications is off-label. We are explicit about that with every patient, and so should anyone else providing this treatment be.

What integration after loss can look like

For the narrow group of patients whose grief has crossed into a diagnosable depression that has not responded to first-line care, ketamine treatment is not framed as a way to make the loss go away. It is not. Anyone selling the idea that an infusion can erase a person you loved is selling something dangerous. Healthy bereavement is not about forgetting. It is about learning to carry what happened alongside the rest of your life.

Where ketamine can plausibly help, in the depression-after-loss subset, is by interrupting the stuck neural patterns that keep a person frozen — the constant rumination, the inability to imagine a future, the collapse of motivation. Some patients describe a brief window of cognitive flexibility after infusions in which they can engage with grief work, rebuild routines, or reconnect with people they had been avoiding. That window is short, and it is wasted without follow-up therapy. Our colleagues in the literature describe an integration period for a reason: the medicine opens a door, the person has to walk through it.

This is also where the lessons we have learned from other forms of perinatal and post-event mood disturbance are useful. The work is rarely the infusion. The work is what the person does in the days and weeks afterward — sleep, reconnection, meaningful activity, therapy.

When we recommend therapy first, ketamine maybe later

If you call our clinic in acute grief — say, in the first weeks or months after a death — we are likely to tell you that ketamine is not the right first step. There is no evidence that medicating early-stage grief improves long-term outcomes, and there are reasonable theoretical concerns that doing so could interfere with the natural integration of the loss. Acute grief is supposed to hurt. Numbing it on a chemical schedule is not the same as healing.

Months out, when grief has stopped moving and the person can describe a clear pattern of being stuck — the same intrusive longing, the same inability to function, the same shrinking life — and especially when a clinician has identified an overlay of major depression, the conversation changes. At that point we want to know what therapy has been tried, what medications have been tried, who is screening for prolonged grief disorder, and whether a treatment-resistant depression workup is appropriate.

Often, the most useful thing we can do is recommend a grief-trained therapist before considering anything we offer. There is real signal in the Shear research, in the broader psychotherapy literature, and in clinical experience that structured grief work is the foundation. Medication, when it has a role, is built on that foundation.

How we hold space without overpromising

For patients who do go forward with treatment after careful screening and clinician coordination, the clinical setup at Music City Ketamine is the same as for any other off-label psychiatric use. Marla Peterson, CRNA, oversees every infusion and provides anesthesia-level monitoring throughout the session. Continuous pulse oximetry, blood pressure, and heart rate are tracked. Private rooms, low light, and our clinic dogs Walter White and Wilma create an environment that takes the medical edges off without pretending the work itself is simple.

Cost is straightforward. Insurance does not generally cover off-label IV ketamine. Sessions at our clinic are $475 each, and we are upfront about that before anyone schedules. We will also be upfront if we think the treatment is not the right fit for what you are going through, and we have referred grieving people back to therapy more often than we have brought them into the infusion room.

Research suggests the depression evidence is strong; data shows ketamine can be useful in carefully selected patients with treatment-resistant mood disorders. Evidence for prolonged grief disorder specifically is not yet there. We will not pretend otherwise. If grief has gotten stuck and you are not sure what to do, the right next step is almost always a clinician you trust, not a clinic. If that clinician thinks a conversation with us makes sense, we are glad to have it.